Evidence map›Paper›PMID 37851293›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024

Neurological complications due to copper deficiency in the context of Wilson disease treatment: a case report with long-term follow-up and review of the literature.

Danilo Tornabene, Paola Bini, Matteo Gastaldi, Elisa Vegezzi, Carlo Asteggiano, Enrico Marchioni, Luca Diamanti

Open access · hybridAbstract readCase ReportsReview
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Wilson's disease: does a neuropsychiatric phenotype without liver involvement truly exist?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 3 countries.

Danilo TornabeneDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. danilo.tornabene01@universitadipavia.it.ORCID http://orcid.org/0009-0006-1153-3613
Paola BiniIRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.
Matteo GastaldiIRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.
Elisa VegezziIRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.
Carlo AsteggianoDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Enrico MarchioniIRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.
Luca DiamantiIRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.
University of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective is to investigate the presentation, complications, management, and outcomes of copper deficiency-induced neurological pathologies due to Wilson disease (WD) overtreatment. We examined the case of a WD patient who developed a low thoracic dorsal myelopathy due to chronic hypocupremia from excessive zinc therapy. A comprehensive literature review was conducted to identify similar cases. Ten additional cases of neurological pathology resulting from copper deficiency in the context of WD over-treatment were identified, all occurring during therapy with zinc salts. Myelopathy and peripheral neuropathy were the most common complications, while two additional groups reported leukoencephalopathy. Early cytopenia was often associated with copper deficiency-related neurological pathology appearing early in the context of copper deficiency. WD patients undergoing treatment, especially with zinc salts, should be closely monitored to prevent over-treatment and the consequent copper deficiency. Regular complete blood counts could provide early detection of copper deficiency, avoiding irreversible neurological damage. Swift recognition of new neurological signs not consistent with WD and timely discontinuation of the decoppering therapy are critical for improving outcomes. The optimal management, including the potential benefit of copper supplementation in patients with WD and subsequent therapy adjustments, remains unclear and necessitates further investigation. Despite the general poor functional neurological outcomes, there were some exceptions that warrant further exploration.

Indexed as

Hepatolenticular DegenerationSpinal Cord DiseasesCopperFollow-Up StudiesHumansSaltsZincCopperSaltsZincCopper deficiencyCopper supplementationMyelopathyNeuropathyWilson diseaseZinc

Identifiers

PMID37851293
PMCPMC10858109
OpenAlexW4387729387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.